Clinical Trial Detail

NCT ID NCT02339922
Title Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

Waldenstroem's macroglobulinemia

follicular lymphoma

mantle cell lymphoma

marginal zone B-cell lymphoma

CLL/SLL

Therapies

Ixazomib + Rituximab

Age Groups: senior adult

No variant requirements are available.